Research Topics
| David L WylesSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Antiviral resistance and the future landscape of hepatitis C virus infection therapyDavid L Wyles
Division of Infectious Diseases, University of California San Diego, La Jolla, CA, USA
J Infect Dis 207:S33-9. 2013..Promising results from early stages of interferon-free trials will be reviewed...- Hepatitis C virus drug resistance: implications for clinical managementDavid L Wyles
Division of Infectious Diseases, University of California, San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
Infect Dis Clin North Am 26:967-78. 2012..Finally, resistance considerations for other classes of inhibitors and the rapidly approaching interferon-free therapeutics regimens are offered... 
Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatmentEdward R Cachay
Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
AIDS Res Ther 8:29. 2011..abstract:..
Development of herpes simplex virus disease in patients who are receiving cidofovirDavid L Wyles
Division of Infectious Diseases, University of California, San Diego, CA, USA
Clin Infect Dis 41:676-80. 2005..In vitro resistance to cidofovir has been reported with use of laboratory HSV strains; clinical failure of cidofovir therapy for HSV disease has also been reported with an isolate that was susceptible by in vitro testing...- Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targetsDavid L Wyles
Department of Medicine, Divivion of Infectious Diseases, University of California San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
J Virol 81:3005-8. 2007..These results suggest that combinations of inhibitors with different mechanisms of action should be prioritized for assessment in clinical trials for chronic hepatitis C virus infection... - Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitorsDavid L Wyles
Division of Infectious Diseases, Department of Medicine, University of California, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA
Antimicrob Agents Chemother 52:1862-4. 2008..ACH-806 is a hepatitis C virus NS4A inhibitor with a novel mechanism of action and resistance pathway. This compound was synergistic with NS3 protease inhibitors and NS5B nucleoside and nonnucleoside polymerase inhibitors... - Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replicationNadejda Valiaeva
Division of Infectious Diseases, University of California, San Diego, USA
Bioorg Med Chem 19:4616-25. 2011..The most active anti-HIV compound was octadecyloxyethyl 9-(R)-[3-methoxy-2-(phosphonomethoxy)propyl]guanine with an EC₅₀ < 0.01 nanomolar and a selectivity index of > 4.4 million... - 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replicationChristian Grünberger
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, USA
J Infect Dis 197:42-5. 2008..We formally demonstrate synergistic antiviral activity with 3-drug combinations in this model, further supporting the concept of clinical investigations of combination therapy for HCV infection... - The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A repliconsDavid L Wyles
San Diego Veterans Medical Research Foundation and the Department of Medicine, Division of Infectious Disease, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0676, USA
Antimicrob Agents Chemother 53:2660-2. 2009..In genotype 1A and 1B replicons analyzed by HCV RNA analysis, ODE-(S)-HPMPA was the most active compound, with EC(50)s of 1.8 and 2.1 microM, respectively... - Rong's numbers: accelerating progress in HCV therapeutic researchDavid L Wyles
Division of Infectious Diseases, University of California, San Diego, San Diego, CA 92093, USA
Sci Transl Med 2:33ps25. 2010.... - Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitchesSergey M Dibrov
Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
Proc Natl Acad Sci U S A 109:5223-8. 2012..The presence of a well-defined ligand-binding pocket within the highly conserved IRES subdomain IIa holds promise for the development of unique anti-HCV drugs with a high barrier to resistance... - Conformational inhibition of the hepatitis C virus internal ribosome entry site RNAJerod Parsons
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California, USA
Nat Chem Biol 5:823-5. 2009.... - Moving beyond interferon alfa: investigational drugs for hepatitis C virus infectionDavid L Wyles
University of California San Diego, La Jolla, CA, USA
Top HIV Med 18:132-6. 2010.... - Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trialsLynn E Taylor
Department of Medicine, Brown University, Providence, Rhode Island, USA
Clin Infect Dis 52:812-8. 2011..Whether this is occurring across the United States is unknown... - Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunctionDavid L Wyles
Department of Medicine, Divisions of Infectious Diseases and Clinical Pharmacology, University of Colorado Health Sciences Center, Denver, USA
Clin Infect Dis 40:174-81. 2005....
Research Grants
- An in vitro system to study antiviral strategies against Hepatitis C virusDAVID WYLES; Fiscal Year: 2007..The Description section was not included in the original submission of the amended application. ..